Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Cancer Science|November 22, 2014
Methylation-induced downregulation of TFPI-2 causes TMPRSS4 overexpression and contributes to oncogenesis in a subset of non-small-cell lung carcinomaJunko Hamamoto, Kenzo Soejima, Katsuhiko Naoki, et al.
Lung Cancer (Amsterdam, Netherlands)|November 19, 2013
Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancerKeiko Ohgino, Kenzo Soejima, Hiroyuki Yasuda, et al.
Anticancer Research|January 1, 2015
FOXD1 expression is associated with poor prognosis in non-small cell lung cancerSohei Nakayama, Kenzo Soejima, Hiroyuki Yasuda, et al.
Japanese Journal of Clinical Oncology|January 24, 2015
A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancerShinnosuke Ikemura, Katsuhiko Naoki, Hiroyuki Yasuda, et al.
Translational Oncology|January 5, 2025
TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancersKimberly J Briggs, Kevin M Cottrell, Matthew R Tonini, et al.
Cancer Chemotherapy and Pharmacology|January 8, 2015
A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancerKenzo Soejima, Katsuhiko Naoki, Kota Ishioka, et al.
Molecular and Clinical Oncology|April 29, 2017
Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)Masayoshi Miyawaki, Katsuhiko Naoki, Satoshi Yoda, et al.
Nature Communications|August 11, 2019
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical modelsRyohei Katayama, Bo Gong, Noriko Togashi, et al.
JCO Precision Oncology|January 16, 2018
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung CancerJustin F Gainor, Diane Tseng, Satoshi Yoda, et al.
NPJ Precision Oncology|August 18, 2020
Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibitionJessica J Lin, Adam Langenbucher, Pranav Gupta, et al.
Pageof 6